diagnostics

Tests that detect and monitor disease: lab instruments, test kits and molecular and genetic testing.

Industry · 7 companies · 5 report it as a revenue line

Show
8-K events
Match any selected event
8-K event types
More events

Only filters 8-Ks. Other selected forms stay visible.

  • ABT Abbott Laboratories

    Sells it 25%, $3.3B a quarter“Diagnostics rose 46.7% in Q3 (46.6% excluding FX); 9M sales were $8.577B versus $6.480B, up 32.4% reported and 30.8% excluding FX.”

    Latest 8-KExecutive pay ·

    Change-in-control agreements extended through Dec. 31, 2028 for named executives except CEO Robert B. Ford, whose agreement expires Dec. 31, 2026.

  • AME Ametek

    Sells it“ophthalmic diagnostics”

    Latest 8-KDebt financing ·

    Senior note offerings in U.S. and Canadian dollars and €1.5B in euros will fund debt repayment and general corporate purposes.

  • BRKR Bruker

    Sells it, part of BSI CALID“Develops, manufactures, and distributes innovative solutions for microbial identification, antibiotic resistance and susceptibility testing, polymerase chain reaction (“PCR”) based molecular diagnostic solutions for culture-free infectious disease diagnostics, histology, cellular staining, osmolarity testing as well as monoclonal antibodies and recombinant proteins as raw materials for diagnostic assays.”

    Latest 8-KLeadership change ·

    Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.

  • CDNA CareDx, Inc

    Sells it 85%, $322.9M a year“Our commercially available post-transplant testing services consist of AlloSure® Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap® Heart, a gene expression profiling solution for heart transplant patients, AlloSure® Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure® Lung, a dd-cfDNA solution for lung transplant patients.”

    Latest 10-QQ3 FY2026Positive ·

    Naveris adds NavDx oncology testing as lab products exit; accelerating transplant demand and older-test revenue recognition fuel growth.

    • Revenue$139.4MYoY +39.3%
    • Net income$19.3Mvs $1.7M year ago
  • DHR Danaher Corporation

    Sells it 44%, $2.9B a quarter“Clinical diagnostics growth more than offset weaker respiratory testing.”

    Latest 8-KPositiveEarningsGuidance raised ·

    Improving end markets accelerated core growth outside respiratory testing; FY2026 adjusted EPS guidance rose to $8.57–$8.62.

  • MYGN Myriad Genetics

    Sells it 100%, $824.5M a year“We develop and commercialize molecular tests that help patients and providers uncover genetic insights.”

    Latest 8-KExecutive pay ·

    One-time retention options for the CFO, COO and chief scientific officer support leadership continuity as Myriad works to improve efficiency.

  • TMO Thermo Fisher Scientific

    Sells it 10%, $4.6B a year“Our Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.”

    Latest 8-KLeadership change ·

    Executive Vice President Michael D. Shafer will retire effective Dec. 31, 2026.

Feedback